Quantcast

Latest kidney cancer Stories

2008-09-05 06:00:23

Cancer drug developer Antisoma has started a Phase II study of AS1411 in metastatic renal cell carcinoma. The single-arm trial will enroll around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib). It will evaluate the safety and efficacy of AS1411 monotherapy given at 40 mg/kg/day for four days every 28 days for up to two cycles. Efficacy measures in the trial include response rate, time to progression...

2008-09-04 03:00:25

London, UK: 04 September 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer). The single-arm trial will enrol around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib). It will evaluate the safety and efficacy of AS1411 monotherapy given at 40 mg/kg/day for four days every 28 days...

2008-08-09 06:00:22

By Barry Nelson A CANCER patient who has survived in the past year because of a wonder drug has condemned plans to deny it to other patients because of the cost. Stan Craddock, 63, from Darlington, said he survived the past ten months because of the drug Sutent. Last night, he said he could not believe that such a powerful cancer drug was effectively going to be banned by the NHS. This followed the draft guidance from the National Institute for Health and Clinical Excellence (Nice)...

2008-08-07 18:00:23

By Emma Brady Midland cancer experts have hit out at a decision to deny kidney cancer patients four drugs under new NHS guidelines issued yesterday. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) which cost between pounds 20,000 and pounds 35,000 per patient per year. This leaves just one cancer drug, interferon, to which many patients...

2008-08-07 18:00:00

By HELEN RAE PATIENTS with advanced kidney cancer will be denied four life- extending treatments on the NHS because they are not cost effective. The National Institute for Health and Clinical Excellence (Nice) yesterday issued draft guidance rejecting the drugs Sutent (Sunitinib), Avastin, Nexavar and Torisel. Charities expressed outrage at the decision, saying it left patients only one treatment option - Interferon - to which many do not respond. Cancer sufferer Ken Potts, 55, of...

2008-08-07 12:00:18

By JANE KIRBY Broadcaster James Whale accused a health watchdog today of being "barbaric" in denying kidney cancer patients access to four drugs. The star, who was diagnosed with the disease in 2000 and set up a charity to raise awareness, said the National Institute for Health and Clinical Excellence (Nice) was a "very badly named organisation". He slammed Nice's decision - which is subject to appeal - to deny patients access to Sutent (sunitinib), Avastin (bevacizumab), Nexavar...

2008-07-31 09:01:26

Antigenics Inc. (NASDAQ: AGEN) reported results today for the quarter ended June 30, 2008. The company incurred a net loss attributable to common stockholders of $12.2 million, or $0.19 per share, basic and diluted, for the second quarter of 2008, compared with a net loss attributable to common stockholders in the second quarter of 2007 of $10.1 million, or $0.22 per share, basic and diluted. For the six months ended June 30, 2008, Antigenics incurred a net loss attributable to common...

2008-07-21 12:01:26

A study of patients with kidney cancer has shown that radiofrequency ablation, a minimally invasive, kidney-sparing procedure, can be a successful treatment option for patients whose cancer has not spread beyond the kidney, report researchers at Wake Forest Baptist Medical Center. Results from the three year study, which evaluated 22 patients who received the treatment, are published in the July issue of the American Journal of Roentgenology. The treatment uses computed tomography to guide...

2008-07-16 06:00:13

By Annette Wells By ANNETTE WELLS REVIEW-JOURNAL Randy Irwin is the ultimate guinea pig. He's the first to try out an experimental treatment by New Jersey- based Medarex for kidney cancer to determine whether it works and to observe possible side effects. Hopes were that his tumor would shrink or disappear - or at the very least remain in check - because of the treatment. But earlier this month the 50-year-old Las Vegas resident learned that, after three treatments in six weeks,...

2008-07-07 12:00:12

Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ. But that could change, thanks to a new molecule found by Stanford University School of Medicine researchers that kills kidney cancer cells. Ideally, the researchers said, a drug created from this molecule would help fight the life-threatening disease while leaving patients' kidneys intact. "You now have a potential means of going after a disease that's been difficult to treat," said...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related